Delcath Systems, Inc. (DCTH)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$14.49-2.23%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · DCTH
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 54.3% |
| Our one-year growth estimate | diamond | 32.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 22.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of —
DCTH — officer change
Dated 2026-05-14
The filing details an amendment to the equity incentive plan, not a management change.
Why it matters: The trial tests HEPZATO with standard care in liver-dominant breast cancer. Starting and advancing it would show progress beyond the current approved use.
Supportive ifThe company reports that more patients have started the global Phase 2 trial after its first patient was dosed.
Worry ifThe company reports that the trial is paused, delayed, or ended before further patients are dosed.
Why it matters: HEPZATO revenue and active centers show whether use is spreading beyond current sites. Q2 had 31 active centers and $27.1 million in HEPZATO revenue.
Watch forQ3 HEPZATO revenue is above $27.1 million and active treatment centers rise above 31.
Also watch forQ3 HEPZATO revenue is below $27.1 million or active treatment centers fall below 31.
Why it matters: Second-quarter gross margin was 90%, above the new 86% to 89% range. A lower full-year result would show that this gain did not last.
Worry ifThe 2026 report shows full-year gross margin below 86%.
Less concerning ifThe 2026 report shows full-year gross margin at or above 86%, within or above the updated range.
Why it matters: The company posted positive adjusted EBITDA in both reported 2026 quarters. The full-year goal tests whether that trend holds.
Supportive ifThe 2026 results report positive adjusted EBITDA for the full year.
Worry ifThe 2026 results report adjusted EBITDA at zero or below for the full year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$177 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $384 loss on $10,000 · 3.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,168 loss on $10,000 · 21.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.